GlassScriptPhysician profile
Steven Lansman
NPI 1982639613
$3,536.59
in general payments reported to CMS, 2019-2025
8 companies · $718 in 2025
The $718 reported for 2025 was less than what a typical Thoracic Surgery (Cardiothoracic Vascular Surgery) provider received nationally (typical 2025 total: $796).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $19.74 · 2021: $90.89 · 2022: $391 · 2023: $1,439 · 2024: $878 · 2025: $718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,035.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,034.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,493.82 | 2023-2024 | |
| W. L. Gore & Associates, INC. | $749.33 | 2024-2025 | Gore Excluder Thoracoabdominal Branch Endoprosthesis, Gore Tag Thoracic Branch Endoprosthesis, Gore Tag Conformable Thoracic Stent Graft |
| Medtronic, INC. | $379.09 | 2022-2023 | Endurant Iis |
| Kerecis Limited | $331.14 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Allergan, INC. | $324.04 | 2021-2022 | |
| Cook Medical LLC | $220.52 | 2024 | Zenith Spiral-Z |
| Abbott Laboratories | $19.74 | 2020 | |
| Recor Medical INC | $18.91 | 2025 | Paradise Ultrasound Renal Denervation System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Lansman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.